Human Immunodeficiency Virus Type 1 (HIV-1) immune system interaction (HIV-1/Immune System)

The Human Immunodeficiency Virus Type 1 (HIV-1) immune system interaction describes the complex pathological process where HIV-1 infects and depletes host immune cells, primarily CD4+ T lymphocytes, macrophages, and dendritic cells (NIH, 2023). The virus utilizes the host's cellular machinery to replicate, eventually leading to the depletion of CD4+ T cells and the onset of Acquired Immunodeficiency Syndrome (AIDS) (CDC, 2022). The host immune system responds via innate and adaptive mechanisms, including the production of HIV-specific CD8+ T cells and neutralizing antibodies, though the virus often evades these through rapid mutation and latent reservoir formation (Nature Reviews Immunology, 2018). Therapeutic intervention focuses on Antiretroviral Therapy (ART), which targets specific viral enzymes or host cell receptors to suppress viral replication and allow for partial immune recovery (FDA, 2023). Because this entry describes a broad biological system rather than a single molecular entity, it is not classified as a discrete therapeutic target.

Other names

HIV-1 pathogenesisHIV-host interactionHIV-1 infection

Antiretroviral drugs inhibit specific stages of the HIV-1 life cycle, such as viral entry, reverse transcription, integration, and protein cleavage, to suppress viral load and prevent immune degradation.